Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Arimenda (ADS-8704, MDX-8704)
print preview
bookmark
share with colleague
General Information
Company
Adamas Pharmaceuticals Inc.
Description
Fixed dose combination of extended release memantine and donepezil
Molecular Target
Mechanism of Action
Latest Stage of Development
Phase III
Indication
Alzheimer's disease (AD)
Partner
Forest Laboratories Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information